Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease.

Abstract: Provided herein are methods of detecting a cancer or a pre-cancer in a subject. In these methods the amount of antibody or antibody fragment bound to an epitope of a S2-6 DNA binding protein or, alternatively, the amount of S2-6 mRNA expression in a first tissue sample from the subject suspected of being cancerous or precancerous is compared with the levels of binding or expression, respectively, in a second sample taken from healthy tissue as the same type as the first sample. No binding or a lesser binding of the antibody or antibody fragment, or, alternatively, no S2-6 mRNA expression or lesser expression by the first sample as compared to that of the second sample is indicative of a cancer or a pre-cancer in the subject. Also provided are methods of treating a cancer or a pre-cancer in a subject. Kits are provided to perform the methods disclosed herein.

Abstract: A substantially pure S2-6 protein (a) having a zinc binding LIM domain, (b) whose mRNA is preferentially expressed in nonproliferating or growth inhibited human diploid fibroblasts, (c) whose mRNA is overexpressed in senescent human diploid fibroblasts or human diploid fibroblasts derived from a patient with Werner Syndrome, and (c) whose mRNA expression is reduced or abolished in fetal human diploid fibroblasts, immortalized cells, cancerous cells and other highly proliferative cells.

Abstract: A substantially pure S1-3 protein (a) being a DNA binding protein containing three zinc finger domains, (b) whose mRNA is overexpressed in senescent human diploid fibroblasts or human diploid fibroblasts derived from a patient with Werner Syndrome, and (c) whose mRNA is not expressed in fetal human diploid fibroblasts.